The relationship between the long noncoding RNA (lncRNA) expression and oesophageal cancer prognosis has been widely studied, but less consensus has been reached. We conducted this study to evaluate the relationship between the expression of lncRNAs and the prognosis and clinical pathology of oesophageal cancer. We conducted a systematic search of PubMed, EMBASE and Cochrane Library until 25 January 2019. Studies that evaluated the associations of a specific lncRNA with survival and/or clinicopathology of oesophageal cancer were included. Pooled hazard ratios (HRs), odds ratios (ORs), and corresponding 95% confidence intervals (CIs) were calculated using fixed or random-effect models. Sensitivity analysis was used to verify the stability of results. Publication bias was detected using Begg tests and adjusted utilizing the trim-and-fill method if a bias existed. A total of 51 studies comprising 6510 patients and regarding 41 lncRNAs were included in the present systematic review and meta-analysis. The results showed that dysregulation of lncRNAs was associated with overall survival, disease-free survival, and progression-free survival. The expression of lncRNAs was related to some certain clinicopathological parameters of oesophageal cancer, including tumour size, T classification, lymph node metastasis, tumour node metastasis (TNM) stage and differentiation. Among these findings, lncRNA AK001796, CASC9, HOTAIR, MALAT1 and UCA1 were identified and were expected to be ideal biomarkers for the prognosis and clinicopathology of oesophageal cancer. Although significant publication bias was observed in some studies, the results were not changed after adjustment using the trim-and-fill method. Abnormal lncRNA-expression profiles could serve as a promising indicator for prognostic evaluation of patients with oesophageal cancer. The combination of these lncRNAs will contribute to clinical decision-making in the future.

中文翻译：

---

异常表达的lncRNAs在食管癌预后和临床病理学中的系统评价和荟萃分析

长链非编码RNA（lncRNA）表达与食管癌预后之间的关系已被广泛研究，但尚未达成共识。我们进行了这项研究，以评估 lncRNA 的表达与食管癌预后和临床病理之间的关系。我们对 PubMed、EMBASE 和 Cochrane 图书馆进行了系统搜索，直到 2019 年 1 月 25 日。包括评估特定 lncRNA 与食管癌生存和/或临床病理学关联的研究。使用固定或随机效应模型计算合并风险比 (HR)、优势比 (OR) 和相应的 95% 置信区间 (CI)。灵敏度分析用于验证结果的稳定性。使用 Begg 测试检测发表偏倚，如果存在偏倚，则使用修剪和填充方法进行调整。本系统评价和荟萃分析共纳入了 51 项研究，包括 6510 名患者和 41 种 lncRNA。结果表明，lncRNAs的失调与总生存期、无病生存期和无进展生存期相关。lncRNAs的表达与食管癌的某些临床病理参数有关，包括肿瘤大小、T分型、淋巴结转移、肿瘤淋巴结转移（TNM）分期和分化。在这些发现中，lncRNA AK001796、CASC9、HOTAIR、MALAT1和UCA1被鉴定出来，有望成为食管癌预后和临床病理学的理想生物标志物。尽管在一些研究中观察到了显着的发表偏倚，但使用修整法调整后结果并未改变。异常的 lncRNA 表达谱可以作为食管癌患者预后评估的有希望的指标。这些 lncRNA 的组合将有助于未来的临床决策。